Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2016 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Host an Analyst and Investor Reception

SAN RAMON, Calif., April 14, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and...
April 11, 2016 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Patent and Trademark Office Against a United Therapeutics Patent

SAN RAMON, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
March 29, 2016 16:05 ET | Source: SteadyMed Therapeutics

SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results

SAN RAMON, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
February 17, 2016 16:15 ET | Source: SteadyMed Therapeutics

SteadyMed to Present at RBC Capital Markets 2016 Global Healthcare Conference

SAN RAMON, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and...
February 02, 2016 16:15 ET | Source: SteadyMed Therapeutics

SteadyMed to Present at 18th Annual BIO CEO & Investor Conference

SAN RAMON, Calif., Feb. 02, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and...
January 06, 2016 08:00 ET | Source: SteadyMed Therapeutics

Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency

VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
January 05, 2016 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension

SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
December 07, 2015 07:00 ET | Source: SteadyMed Therapeutics

SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin

SAN RAMON, Calif., Dec. 7, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...
November 12, 2015 16:05 ET | Source: SteadyMed Therapeutics

SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results

SAN RAMON, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
November 05, 2015 07:30 ET | Source: SteadyMed Therapeutics

SteadyMed to Report Recent Developments and Third Quarter 2015 Financial Results

SAN RAMON, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right